Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms...

Descripción completa

Detalles Bibliográficos
Autores principales: Suwaidi, Jassim Al, Salam, Amar M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59641/
https://www.ncbi.nlm.nih.gov/pubmed/11806792
http://dx.doi.org/10.1186/cvm-2-4-171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59641/
https://www.ncbi.nlm.nih.gov/pubmed/11806792
http://dx.doi.org/10.1186/cvm-2-4-171

Ejemplares similares